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Summary.-I have studied the effects on growth of two tumours in mice and on host
toxicity, of combining Misonidazole (MISO) or Metronidazole (METRO) with
Methotrexate (MTX), 5-fluorouracil (FU) or Adriamycin (ADR). The nitroimidazoles
alone had no effect on the growth of either tumour, but MISO (1 mg/g) led to a small
increase in delay to regrowth of the 16/C mammary carcinoma but not the KHT
fibrosarcoma, when given after X-irradiation.
MTX was active only against the KHT tumour, and growth delay was not increased
by the addition of MISO or METRO. FU delayed growth of both tumours, and growth
delay was increased slightly by single-dose MISO. ADR was active only against the
16/C tumour, and delay to regrowth was increased by adding MISO.
Host toxicity assessed by death and loss of body weight was much greater when
MISO or METRO were added to MTX, and a little greater when they were added to
FU. ADR plus MISO caused no deaths and no greater loss of body weight than ADR
alone. The addition of MISO to treatment with anticancer drugs led to a slightly
greater and more prolonged myelosuppression.
METRO and MISO increase the anti-tumour effects of some anti-cancer drugs,
but may also increase host toxicity. Nitroimidazoles should be used with caution in
combination with chemotherapy.
MANY solid tumours have a poor blood
supply and contain hypoxic cells that are
resistant to treatment with radiation.
Hypoxic and other poorly nourished cells
may also limit the effectiveness of chemo-
therapy for a number of reasons. The
concentration of anti-cancer drugs in such
cells may be low because of their position
relative to the blood supply, as demon-
strated in tumours and spheroids by
studying the fluorescence of ADR (Ozols
et al., 1979; Sutherland et al., 1979). Also,
poorly nourished tumour cells tend to be
slowly proliferating (Tannock, 1968, 1970;
Hirst & Denekamp, 1979) whereas most
anti-cancer drugs are more active against
rapidly proliferating cells (Tannock, 1978).
Finally, drug uptake or activity might be
influenced by the nutritional state of the
cells or by neighbouring tumour necrosis.
If hypoxic cells in solid tumours are
resistant to some anti-cancer drugs, an
improved therapeutic index (i.e. ratio of
tumour damage to normal tissue damage)
might be achieved by including in drug
combinations agents with selectivetoxicitv
for hypoxic cells. MISO and METRO
are drugs that have been found to have
greater toxicity for hypoxic cells than for
aerobic cells in tissue culture (e.g. Mohin-
dra & Rauth, 1976; Moore et al., 1976;
Stratford & Adams, 1977; Taylor & Rauth,
1978) and to induce necrosis of hypoxic
cells in the centre ofmulticellular spheroids
(Sridhar et al., 1976). At high concentra-
tion, the same drugs have good penetra-
tion into hypoxic regions of tumours, and
have been shown to kill hypoxic cells in
some, but not all, mouse tumours (Foster
et al., 1976; Brown, 1977; Denenkamp,
1978; Pederson et al., 1979). Also MISO
may be metabolized in hypoxic tumourI. F. TANNOCK
regions, with release of metabolites that
can kill neighbouring better-oxygenated
cells (Brown, 1977; Brown & Yu, 1979).
The present series of experiments was
designed to study the effect of combining
MISO or METRO with conventional anti-
cancer drugs on the response oftwo experi-
mental tumours, and on host toxicity.
BothsingleandmultipledosesofMISO and
METRO have been studied, because the
half-lives of the drugs in mice (-1 h) are
shorter than in man ( 10 h). Metho-
trexate, 5-fluorouracil, and Adriamycin
were chosen for study bec4use they are
used commonly to treat solid tumours in
man, have selective toxicity for proliferat-
ing cells, and because ADR is known to
have poor penetration from blood vessels.
Experiments in which MISO or METRO
were given after X-irradiation to the
tumours are included in order to assess the
in vivo toxicity of the drugs for hypoxic
tumours.
MATERIALS AND METHODS
Animals and Tumours.-C3H male mice
(Flow Laboratories) at least 10 weeks old
were used in all experiments. Experimental
tumours were the KHT fibrosarcoma and the
16/C mammary adenocarcinoma. The KHT
tumour has been serially transplanted in our
laboratory, and is known to respond to some
anti-cancer drugs and to contain hypoxic
cells (Lin & Bruce, 1972; Hill & Bush, 1977).
The 16/C tumour was obtained from the NCI
tumour bank atMasonResearchLaboratories,
Worcester, Massachusetts, and subsequently
has been serially transplanted; it is known to
respond to several anti-cancer drugs including
ADR and FU (Corbett et al., 1978). For
implantation of tumours a single cell suspen-
sion was obtained by a method described
previously (Thomson & Rauth, 1974) and
2 x 105 cells were injected into the left
hind leg ofeach animal. Both types oftumour
will grow progressively from implants of 100
cells.
Growth curves for the tumours were
generated as follows. Tumour diameter was
recorded to the nearest 0 5 mm by passing the
leg through a series of graded holes drilled in
perspex, and the tumour weight was estima-
ted from this measurement by a previously
defined calibration curve. Animals were coded
with numbered ear tags prior to treatment,
and randomized groups of 6-8 mice received
various treatments. Treatment was given
when tumours had a mean diameter of 8-9
mm (weight 0 3 g). Tumour diameter and
animal weight were then recorded at 1-3-day
intervals by an observer who was unaware of
the treatment history. Mean tumour weight
and its standard error were plotted against
time after treatment. Most experiments were
repeated to check reproducibility.
DrugsandRadiation.-Methotrexate (MTX
Lederle), 5-fluorouracil (FU, Roche) and
Adriamycin (ADR, Adria Laboratories) were
standard parenteral formulation obtained
from our hospital pharmacy. Metronidazole
(METRO) was donated byPoulenc (Montreal)
and Misonidazole (MISO) by Roche (Welwyn
Garden City, England). All drugs were diluted
to an appropriate concentration with physio-
logical saline shortly before use.
All the anti-cancer drugs were given in a
fluid volume of 0 01 ml/g body weight by
i.p. injection. Because of their limited solu-
bility, MISO and METRO were injected i.p.
in volumes of 0-02 or 0 05 ml/g body weight.
Control animals received equal volumes of
saline.
Serum concentration of MISO or METRO
wasmeasured byhigh-pressure liquid chroma-
tography (HPLC, Gudaskas et at., 1978;
Workman et al., 1978). Groups of3 mice were
killed at various times after injection of
MISO or METRO, and heparin was injected
shortly before death to prevent clotting.
Blood samples were collected from the in-
ferior vena cava, and the pooled blood was
centrifuged. Plasma was mixed with methanol
to precipitate protein, filtered and injected
on to the HPLC column. Drug concentration
was obtained from a previous calibration
curve, derived from samples of known con-
centration.
Tumours in some experiments were irra-
diated locally using a double-headed lOOkVp
X-ray unit at a dose rate of 11 Gy/min
(Siemann et al., 1975). Mice were not anaes-
thetized for irradiation.
Assessment of haematoloyical toxicity.-
Haemoglobin levels (Hb) and white blood cell
counts (WBC) were measured f0f individual
mice. A small incision was made in the tail
and 446 ,ul ofblood was collected in aheparin-
ized pipette. The blood was diluted in 10 ml
saline, and analysed using a Coulter Counter
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Model SSr. Blood smears were also prepared
and differential counts of polymorphs and
other WBCs were recorded for some samples.
The method allowed serial estimation ofblood
counts without killing the animals.
RESULTS
MISO or METRO alone
A single i.p. injection of MISO at a dose
of 1 mg/g was given in many experiments.
This dose was well tolerated and usually
produced only a transient weight loss,
< 5%. The single-dose LD50 for MISO is
- 1-4 mg/g. Multiple i.p. injections of
MISO or METRO were given in other
experiments in an attempt to sustain
plasma levels over 36 h. Nine doses of
0-2 mg/g (MISO) or 0 4 mg/g (METRO)
weregiven at 4hintervals; these doseswere
30-50% ofLD50 but caused no deaths, and
weight loss < 5%. Any toxic deaths after
higher doses ofeither drug occurred within
24 h and surviving mice had no apparent
chronic toxicity.
Previous experiments in this laboratory
have shown that peak serum levels of
MISO are proportional to dose (A. M.
Rauth, personal communication). Follow-
ing an i.p. injection of 1 mg/gMISO, serum
levels rose to about 4 mm after 15 min,
and then declined rapidly with a half-life
of 1 h. Serum levels of METRO after
the 1st and 9th of a series of 4h injections
are shown in Fig. 1. Peak levels are similar
(2 mM) so there was little accumulation of
drug, and half life was longer than for
MISO (1.2-1.7 h). Even after 9 injections
there was little tendency to sustain a more
constant drug concentration. There were
marked variations in serum concentration
of METRO and MISO during the course
ofmultiple injections.
Tumour growth curves for the KHT
tumour, following treatment of host
animals with the multiple-dose regimens of
MISO and METRO were generated in
duplicate experiments, and are shown in
Fig. 2. Estimates of tumour weight after
treatment of either the KHT or 16/C
tumours with 1 mg/kg MISO (single dose)
are included in Fig. 3. MISO and METRO
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FIG. 1.-Serum concentration of METRO at various times after the first (A) and ninth (B) injection
of the drug in a dose of 04 mg/g body wt given every 4 h. Each point is obtained from HPLC
analysis of pooled serum from 3 animals.
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FIG. 2.-Growth curves for the KHT tumour treated with multiple doses ofMETRO (A) or MISO (*)
(see text) (0, control). Results are from separate experiments. Means+s.e. for 7-8 tumours are
indicated.
alone have negligible effects on tumour
growth.
Haemoglobin and WBC count were
measured at various times from 1-7 days
after treatment with MISO (1 mg/g single
dose) and compared with values for mice
receiving saline. Some of these data are
included in Table I. There was a tendency
for Hb to fall and WBC to increase in mice
that were bled serially. There were no
differences in mean Hb level between mice
receiving MISO or saline, but in each of 5
experiments mean WBC count was slightly
lower in animals that had received MISO.
However, MISO did not suppress values
of WBC and polymorph counts below the
range found in control animals.
Radiation
Tumour cells which survive moderate or
large doses of radiation in vivo are usually
hypoxic. Therefore MISO or METRO was
given to tumour-bearing mice after 15 Gy
tumour radiation to seek evidence for
killing of hypoxic cells in situ. The drugs
were given after radiation to avoid radio-
sensitization.
Regression and regrowth curves after
irradiation of KHT and 16/C tumours are
shown in Fig. 3. Single dose MISO (1 mg/g)
after radiation led to a small increase in
effect against the 16/C tumour but in only
1 of 2 experiments (shown in Fig. 3B) was
the separation of regrowth curves sig-
nificant. The same dose of MISO had no
effect when given after radiation to the
KHT tumour (Fig. 3A) but a higher dose
(1.2 mg/g) gave short prolongation of
growth delay of about 2 days (not shown).
In further experiments, the 36h course
ofmultiple injections ofMISO or METRO
was commenced immediately after 15 Gy
irradiation to the KHT tumour, or was
given so that the radiation immediately
864NITROIMIDAZOLES AND CHEMOTHERAPY
(B)
0 4 8 12 0 4 8 12 16 20 24
Days after treatment
FIG. 3.-Growth curves for the KHT sarcoma (A) and 16/6 carcinoma (B) treated with saline (0),
MISO (0) (1 mg/kg, single dose) 15 Gy X-rays (A) and 15 Gy X-rays followed immediately by
MISO (A). Means + s.e. for 7-8 tumours are indicated.
TABLE I.-Peripheral white blood cell count (mean + s.e. x 103) at various times after drug
treatment ofC3H mice
Day2 Day3 Day4 Day6
Controls 11-2+1*1 90+04 89+05 20-6+2d1
Misonidazole (1 mg/g) 8 0+0 5 7-6+0 4 6-6+0 5 12-6+1V7
Methotrexate (75 mg/kg) 10-8+0-6 6-3 + 0-6 11-4+1 1 20-1+1 8
MTX+MISO 7-6+1-0 50+0*4 3-6+004 7-6+1-1
5-Fluorouracil (60 mg/kg) 9-5 + 0-7 5-5 + 0-7 8-0 + 0-6 6-3 + 10
FU+MISO 6-8+0-3 6-9+0-3 6-5+0-3 4-3+0-2
Adriamycin (10mg/kg) 79 + 0.5 6-1 + 0-5 6-3 + 0-6 12-7 + 2-5
ADR+MISO 6-2+0-6 6*5+0*4 5-3+0*4 8-5+1-3
preceded the 5th of the 9 injections of
MISO or METRO. In the latter design,
radiation to the KHT tumour was given
4 h after the previous dose of MISO (0.2
mg/g) or METRO (0 4 mg/g) so that
hypoxic cell sensitization is expected to be
minimal. Similar results were obtained for
either drug: there was a small increase in
growth delay of about 2 days if radiation
was delivered within a course of multiple
injections of MISO or METRO, but no
effect when the course of injections was
begun immediately after radiation.
Methotrexate
MTX given as 3 injections of 25 mg/kg
at 4h intervals had no effect on growth of
the 16/C tumour, and the addition of
MISO was also without effect. The same
dose and schedule ofMTX led to a delay in
growth of 2-3 days for the KHT tumour,
and a higher dose of 40 mg/kg/injection
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FIG. 4.-Growth curves for the KHT
sarcoma following treatment with saline
(0), MTX (0) (40 mg/kgx3), MTX+
MISO (0-2 mg/gx9) (LC]) and MTX+
METRO (0 4 mg/g x 9) (A). Means ±s.e. for
6-8 tumours are indicated.
TABLE II.-Weight loss and number of
deaths in mice treated with MTX alone,
or in combination with MISO or
METRO
% Weight loss*
7-6 (5-3-10-1) MTX alone
MTX+MISO
(single dose)
MTX+MISO
(mult. dose)
MTX+METRO
(mult. dose)
Proportion
ofdeathst
1/47
13-0 (9-6-16-2) 2/19
13-6 (11-5-15-7) 3/16
17-0 (16-5-17-4) 6/16
* Mean (range ofmeansinindividual experiments).
t Most died 4-6 days after treatment.
given in the same schedule caused some
regression and delayed tumour growth by
about 4 days. The above dose schedules of
MTX were combined with single dose
MISO (given with the second of 3 MTX
injections), or with the multiple-dose
schedule of MISO or METRO (injections
of MTX given with the 4th-6th injections
ofthe nitroimidazole). Results ofone ofthe
latter experiments are shown in Fig. 4.
MISO or METRO did not increase the
anti-tumour effects of MTX in any
experiment.
MISO and METRO added considerable
toxicity when combined with MTX. There
were more deaths (usually on Days 4-6
after treatment) and more weight loss in
mnice receiving combined treatment (Table
II). Also, the fall in WBC count was lower
and more prolonged when Misonidazole
was added to treatment with MTX (Table
I) though there was no effect on Hb level.
5-Fluorouracil
A single dose of 100 mg/kg FU delayed
growth of the KHT tumour by - 3 days
and of 16/C by 5 days. The same total
dose was more effective against the KHT
tumour when given as a single injection
than as 3 equal doses at 4hintervals. When
a single dose ofFU was given in the middle
of a course of multiple injections of
MISO or METRO to animals bearing the
KHT tumour, there was no increase in
growth delay over those mice receiving
FU alone. A single injection of MISO
(1 mg/g) given simultaneously with FU
led to a small increase in growth delay of
both tumours (Fig. 5).
The addition of a nitromidazole to
treatment with FU increased the toxicity
as measured by death and loss of body
weight (Table III), though the effect was
less than for MTX. The fall in WBC count
was also lower and more prolonged after
combined treatment than after treatment
with FU alone.
TABLE III.-WVeight loss and number of
deaths in mice treated with FU alone,
or in combination with MISO or METRO
FU alone
FU+MISO
(single dose)
FU+MISO
(mult. dose)
FU+METRO
(mult. dose)
Proportion
% Weight loss* of deaths
2-6 (0-6.2) 0/48
7-8 (6.6-9.1) 0/20
4-3 (3.6-5-0) 2/16t
5-6 (3.1-8-0) 3/16t
* Mean (range ofmeansin individual experiments).
t 6-8 days after treatment.
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FIG. 5. Growth curves for thle KHT sarcoma (A) and 16/C carcinoma (B) treated with saline (0),
FU (0) (60 mg/kg in A, 100 mg/kg in B) or FU+MISO (1 mg/g) (A). AMeans+s.e. for6-7 tumours
are in(licate(1.
Adriantycin
Single doses of ADR up to 15 mg/kg i.p.
or 20 mg/kg i.v. were ineffective against
the KHT tumour, and higher doses killed
the animals. In contrast, the 16/C tumour
is known to be sensitive to ADR (Corbett
et al., 1978) and single doses of 10 or 15
mg/kg i.p. caused complete regression of
some tumours (but no cures) and delay to
regrowth of 11-13 days (Fig. 6). Simul-
taneous injection of single-dose MISO
(1 mg/g) with ADR prolonged the delay to
regrowth by 3-5 days (Fig. 6).
Mean loss ofbody weight after combined
treatment with ADR and MISO (8 7%O,
range 4-6-12-2%) was no greater than
after treatment with ADR alone (9.4%,
range 6-8-14-3%). There were no treat-
ment-related deaths in either group, and
MISO could be given with 15 mg/kg i.p.
of ADR (0/12 deaths) even though a
slightly higher dose of ADR alone (20
mg/kg i.p.) was lethal (7/8 deaths).
Myelosuppression after ADR was minimal,
and although WBC count tended to be
slightly lower in mice that also received
MISO, the effect was not significant
(Table I).
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FIG. 6. Growth curves for the 16/C carcinoma treated with saline (0), MISO (1 mg/g) (0), ADR (15
mg/kg in a), 10 mg/kg in b) (A) and ADR +MISO (-). Means + s.e. for 6-7 tumours are indicated.
DISCUSSION
The present experiments were designed
to provide information relevant to two
related questions:
(i) Are there important interactions
between anti-cancer drugs andMISO
or METRO that would encourage
or discourage their combination in
patients?
(ii) Is there evidence for sparing of
hypoxic cells by conventionalchemo-
therapy, and for selective killing of
hypoxic cells by MISO or METRO?
The first of the above questions is of
current and practical importance because
clinical trials ofnitroimidazoles used alone
or in combination with anti-cancer drugs
have been proposed. Current trials of
MISO as a radiation sensitizer are also
including some patients receiving chemo-
therapy. METRO alone was inactive
against colo-rectal carcinoma (Frytak et
al., 1978) but its role in combination
chemotherapy remains to be defined.
However, the results of this and the
succeeding paper show that MISO and
METRO may add considerable toxicity to
conventional anti-cancer drugs. Intro-
duction of such drug combinations in
clinical medicine should be made with
caution, and in Phase I clinical trials to
study toxicity.
The data reported do not answer con-
clusively the second question about the
importance of hypoxic cells in chemo-
therapy. Limited drug delivery to poorly
nourished tumour cells (Ozols et at., 1979),
and their documented low rate of pro-
liferation (Tannock, 1968, 1970; Hirst &
Denekamp, 1979) should convey resistance
to many drugs. However, there is no direct
evidence that the chronicallymalnourished
cells retain clonogenicity and the ability to
re-establish the tumour. There is contrary
evidence in some tumours that the hypoxic
cells which convey resistance to radiation
may be acutelyhypoxic because ofchanges
in blood flow (Brown 1979; Yamaura &
Matsuzawa, 1979). Such transient hypoxia
conveys resistance to radiation because
exposure to radiation is short, but might
have less influence on cell proliferation and
1.0
: O.5
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on drug concentration, unless serum half-
life were also very short. There have been
few direct studies ofthe response to chemo-
therapy of hypoxic and aerobic cells in
solid tumours. Cyclophosphamide was
reported to spare hypoxic cells in a rat
carcinoma but to have no specificity for
B16 melanoma, while BCNU and nitrogen
mustard were reported to spare hypoxic
cells in the B16 melanoma and the KHT
sarcoma respectively (Hill & Stanley,
1975; Hill & Bush, 1977; Dixon et al.,
1978). I am unaware of data for MTX,
FU or ADR.
If chronically hypoxic cells in solid
tumours are both clonogenic and resistant
to conventional chemotherapy, it remains
uncertainwhetherMISO orMETRO can be
given in adequate concentration to kill
surviving hypoxic cells. Experiments in
which these drugs have been given after
radiation have demonstrated hypoxic cell
toxicity in about half the reported studies
(Denekamp, 1978) and in current experi-
ments MISO at 1 mg/g increased the anti-
tumour effect when given after irradiation
to the 16/C but not to the KHT tumour.
In vitro studies of the toxicity of MISO
andMETRO for hypoxic cells suggest that
drug-cell contact time may be more
important than peak concentration (Hall
et al., 1978; A. M. Rauth, personal com-
munication). Sustained but lower serum
concentration of the drugs is more easily
achieved in man where the serum half-
lives of the drugs are much longer than in
mice. Multiple injections were used in
current experiments to try to increase
drug-cell contact time, but also had little
or no effect in prolonging growth delay of
the irradiated KHT tumour. Other factors
that might limit the contact time between
drug and hypoxic cells include a relatively
short life of even "chronically hypoxic"
cells in murine tumours (Tannock, 1968)
and rapid reoxygenation after radiation or
drugs (Hill & Bush, 1977). These factors,
together with a lower temperature in
peripheral murine tumours, and hence
lower sensitivity of hypoxic cells to MISO
or METRO, could lead to a lower prob-
ability of detecting specific toxicity for
hypoxic cells in mice than in man (Strat-
ford & Adams, 1978).
In summary, my results show that
MISO may increase the effectiveness of
FU and ADR against some experimental
tumours, though the observed effects are
small and the mechanism uncertain.
Toxicity was increased when MISO or
METRO were combined with MTX or FU,
and the combination with MTX led to a
decrease in Therapeutic Index. Increased
toxicity was not demonstrated when MISO
was added to ADR but further experi-
ments to assess a range of normal-tissue
toxicity would be essential before conclud-
ing that this combination might convey
therapeutic benefit.
I wish to thank Mrs P. Guttman for her expert
assistance and Dr R. P. Hill for his helpful sugges-
tions. Supported by a Research Grant from the
National Cancer Institue of Canada.
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